About Dyne Therapeutics
Dyne Therapeutics is a company based in Cambridge (United States) founded in 2017.. The company has 191 employees as of December 31, 2024. Dyne Therapeutics offers products and services including DYNE-101, DYNE-251, and DYNE-302. Dyne Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 191 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dyne Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-317.42 M-34.54as on Dec 31, 2024
-
EBITDA
$-341.64 M-42.53as on Dec 31, 2024
-
Latest Funding Round
$115.7 M (USD), Post-IPO
Aug 10, 2020
-
Investors
Citadel
& 7 more
-
Employee Count
191
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Dyne Therapeutics
Dyne Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DYN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Dyne Therapeutics
Dyne Therapeutics offers a comprehensive portfolio of products and services, including DYNE-101, DYNE-251, and DYNE-302. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets DM1 disease to stop progression in neuromuscular patients.
Focuses on DMD disease for improved muscle function.
Addresses FSHD disease to enhance patient outcomes.
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Software Development Team
13 people
Finance and Accounting
6 people
Data Analysis and Operations Team
4 people
Legal and Compliance
4 people
Human Resources and Administration
3 people
Operations Team
3 people
Product Management Team
2 people
Unlock access to complete
Funding Insights of Dyne Therapeutics
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $115.7M
-
First Round
First Round
(03 Apr 2019)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Post-IPO - Dyne Therapeutics | Valuation |
investors |
|
| Apr, 2019 | Amount | Post-IPO - Dyne Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dyne Therapeutics
Dyne Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Atlas Venture and Vida Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dyne Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dyne Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dyne Therapeutics Comparisons
Competitors of Dyne Therapeutics
Dyne Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dyne Therapeutics
Frequently Asked Questions about Dyne Therapeutics
When was Dyne Therapeutics founded?
Dyne Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Dyne Therapeutics located?
Dyne Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
How many employees does Dyne Therapeutics have?
As of Dec 31, 2024, the latest employee count at Dyne Therapeutics is 191.
What does Dyne Therapeutics do?
Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.
Who are the top competitors of Dyne Therapeutics?
Dyne Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
What products or services does Dyne Therapeutics offer?
Dyne Therapeutics offers DYNE-101, DYNE-251, and DYNE-302.
Is Dyne Therapeutics publicly traded?
Yes, Dyne Therapeutics is publicly traded on NASDAQ under the ticker symbol DYN.
Who are Dyne Therapeutics's investors?
Dyne Therapeutics has 8 investors. Key investors include Citadel, Atlas Venture, Vida Ventures, Wellington, and Logos Capital.
What is Dyne Therapeutics's ticker symbol?
The ticker symbol of Dyne Therapeutics is DYN on NASDAQ.